GDTC - CytoMed Therapeutics Limited Quarterly EPS earnings growth
CytoMed Therapeutics profit dynamics rely on successes in the development of gamma-delta T-cell therapies and interest from major pharma behemoths. The GURU.Markets terminal displays a chart of the quarterly EPS growth rate, where 20.40 serves as the base value of the parameter. Growth is constrained by Singapore's strict protocols within the local ecosystem, however, robotic manufacturing guarantees sterility and industrial-scale cultivation of immune cells.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_GDTC_-_CytoMed-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "CytoMed Therapeutics Limited (GDTC): Quarterly EPS earnings growth from 02/21/2024 to 11/14/2026 | 👁️GURU.Markets👁️")
CytoMed Therapeutics Limited - analytical breakdowns and key metrics (GDTC)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Total Debt to Equity Ratio CytoMed Therapeutics|GDTC - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity w2.cytomed.sg|GDTC - Company Cumulative Debt|Debt to Book Capitalization Ratio CytoMed Therapeutics Limited|GDTC - Company Long-Term Liabilities|Company Short-Term Debts CytoMed Therapeutics|Quick Ratio w2.cytomed.sg
- earnings and valuation multiples indicators:
GDTC - Company Profit|Future Profit CytoMed Therapeutics|GDTC - Company Value to Net Income|Projected Price to Earnings w2.cytomed.sg|GDTC - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple CytoMed Therapeutics Limited|GDTC - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) CytoMed Therapeutics|GDTC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months w2.cytomed.sg|GDTC - Earnings per share increase in current year|Earnings growth forecast for next year CytoMed Therapeutics
- revenue and sales proceeds data:
Comprehensive company analysis:CytoMed Therapeutics
CytoMed Therapeutics' development of innovative cell therapy is complicated by geopolitical barriers and disruptions in biological logistics, which directly impact operational efficiency. The net profit per share trend, reflected through recorded quarterly EPS growth, measures the business's real profitability, allowing investors to detect revenue stagnation in a timely manner and minimize capital loss risks amid external sanctions.
Main competitors
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|Aura Bio (AURA) - Quarterly EPS earnings growth|CADL (Candel Therapeutics Inc.) - Quarterly EPS earnings growth|ARAY: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SLS (SELLAS Life Sciences Group, Inc.)|Year-over-year earnings per share growth rate for the last twelve months ACTU|Citius Oncology - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HURA|TARA: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Fate Pharma|Aadi Bioscience Inc (WHWK) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months TScan (TCRX)|Year-over-year net earnings per share growth for the last 12 months CSBR|xbiotech.com (XBIT) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months cel-sci.com (CVM)|OSTX - Earnings per share growth in annualized terms for the last twelve months|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ARTV|ANL - Year-over-year earnings per share growth for the last twelve months|VERU - Quarterly EPS earnings growth|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|XLO: Year-over-year earnings per share growth rate for the last twelve months|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|MURA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|Year-over-year earnings per share growth rate for the last twelve months OKUR|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)
